Literature DB >> 22855136

Surveillance of resected non-small cell lung cancer.

A López-González1, P Ibeas Millán, B Cantos, M Provencio.   

Abstract

Lung cancer is the most common cancer in the world. 15 % of all patients with lung cancer are diagnosed at an early stage, and surgery is the treatment of choice for them. 40 % of all patients survive more than 5 years after surgery, and most of them die as a result of systemic disease. Half of all recurrences are diagnosed within the first 24 months after curative treatment, and 90 % in the first 5 years. Despite this, it is not standardized who should do the monitoring, what additional tests are needed and how often should they be performed. We present here a review on the various recommendations in clinical guidelines.

Entities:  

Mesh:

Year:  2012        PMID: 22855136     DOI: 10.1007/s12094-012-0841-z

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  43 in total

1.  [IFCT-0302 trial: randomised study comparing two follow-up schedules in completely resected non-small cell lung cancer].

Authors:  V Westeel; M P Lebitasy; M Mercier; P Girard; F Barlesi; F Blanchon; J Tredaniel; P Bonnette; M C Woronoff-Lemsi; J L Breton; R Azarian; P E Falcoz; S Friard; L Geriniere; S Laporte; E Lemarie; E Quoix; G Zalcman; J Guigay; F Morin; B Milleron; A Depierre
Journal:  Rev Mal Respir       Date:  2007-05       Impact factor: 0.622

Review 2.  Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer.

Authors:  Helena Linardou; Issa J Dahabreh; Dimitra Kanaloupiti; Fotios Siannis; Dimitrios Bafaloukos; Paris Kosmidis; Christos A Papadimitriou; Samuel Murray
Journal:  Lancet Oncol       Date:  2008-09-17       Impact factor: 41.316

Review 3.  Exhaled biomarkers in lung cancer.

Authors:  I Horváth; Z Lázár; N Gyulai; M Kollai; G Losonczy
Journal:  Eur Respir J       Date:  2009-07       Impact factor: 16.671

4.  Cancer statistics, 2002.

Authors:  Ahmedin Jemal; Andrea Thomas; Taylor Murray; Michael Thun
Journal:  CA Cancer J Clin       Date:  2002 Jan-Feb       Impact factor: 508.702

5.  Cost of patient follow-up after potentially curative lung cancer treatment.

Authors:  K S Virgo; K S Naunheim; L W McKirgan; M E Kissling; J C Lin; F E Johnson
Journal:  J Thorac Cardiovasc Surg       Date:  1996-08       Impact factor: 5.209

6.  Expression of Hsp27 and Hsp70 in lymphocytes and plasma in healthy workers and coal miners with lung cancer.

Authors:  Haijiao Wang; Jingcai Xing; Feng Wang; Wenhui Han; Houmao Ren; Tangchun Wu; Weihong Chen
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2010-08-17

7.  [Follow-up of patients with non-small-cell pulmonary cancer undergoing complete resection. Should surgeons be in charge?].

Authors:  G Varela; M Jiménez; M Hernández-Mezquita
Journal:  Arch Bronconeumol       Date:  1998-01       Impact factor: 4.872

8.  Follow-up and surveillance of the lung cancer patient following curative intent therapy: ACCP evidence-based clinical practice guideline (2nd edition).

Authors:  Jeffrey Rubins; Michael Unger; Gene L Colice
Journal:  Chest       Date:  2007-09       Impact factor: 9.410

9.  Screening for epidermal growth factor receptor mutations in lung cancer.

Authors:  Rafael Rosell; Teresa Moran; Cristina Queralt; Rut Porta; Felipe Cardenal; Carlos Camps; Margarita Majem; Guillermo Lopez-Vivanco; Dolores Isla; Mariano Provencio; Amelia Insa; Bartomeu Massuti; Jose Luis Gonzalez-Larriba; Luis Paz-Ares; Isabel Bover; Rosario Garcia-Campelo; Miguel Angel Moreno; Silvia Catot; Christian Rolfo; Noemi Reguart; Ramon Palmero; José Miguel Sánchez; Roman Bastus; Clara Mayo; Jordi Bertran-Alamillo; Miguel Angel Molina; Jose Javier Sanchez; Miquel Taron
Journal:  N Engl J Med       Date:  2009-08-19       Impact factor: 91.245

10.  Gene promoter methylation assayed in exhaled breath, with differences in smokers and lung cancer patients.

Authors:  Weiguo Han; Tao Wang; Andrew A Reilly; Steven M Keller; Simon D Spivack
Journal:  Respir Res       Date:  2009-09-25
View more
  3 in total

1.  Prognostic potential of microRNA-138 and its target mRNA PDK1 in sera for patients with non-small cell lung cancer.

Authors:  Lihong Han; Guoxiu Zhang; Nali Zhang; Haiyan Li; Yanyan Liu; Aiguo Fu; Youguang Zheng
Journal:  Med Oncol       Date:  2014-07-27       Impact factor: 3.064

2.  Octa-arginine-modified pegylated liposomal doxorubicin: an effective treatment strategy for non-small cell lung cancer.

Authors:  Swati Biswas; Pranali P Deshpande; Federico Perche; Namita S Dodwadkar; Shailendra D Sane; Vladimir P Torchilin
Journal:  Cancer Lett       Date:  2013-02-16       Impact factor: 8.679

3.  Preoperative serum LMTK3 as a novel biomarker in non-small cell lung cancer.

Authors:  Zhaoguo Xu; Xiaoying Qi; Xiaoye Zhang; Li Yu
Journal:  Tumour Biol       Date:  2014-02-09
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.